John Vraciu
Child & Adolescent Psychiatry · Canton, OHNPI 1962638239
Payments from drug & device makers
Across 709 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$1K
- Corium, LLC$1K
- Tris Pharma Inc$963
- Otsuka America Pharmaceutical, Inc.$907
- Ironshore Pharmaceuticals Inc.$825
- plus $5K from 28 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$11,34899%
- Education$581%
- Gifts$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 109 | $1,304 |
| Alkermes, Inc. | 57 | $1,066 |
| Corium, LLC | 62 | $1,049 |
| Tris Pharma Inc | 82 | $963 |
| Otsuka America Pharmaceutical, Inc. | 48 | $907 |
| Ironshore Pharmaceuticals Inc. | 51 | $825 |
| Takeda Pharmaceuticals U.S.A., Inc. | 49 | $771 |
| Supernus Pharmaceuticals, Inc. | 22 | $664 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $642 |
| Neos Therapeutics, LP | 51 | $564 |
| Axsome Therapeutics, Inc. | 15 | $403 |
| Lundbeck LLC | 20 | $368 |
| Indivior Inc. | 25 | $353 |
| Johnson & Johnson | 13 | $233 |
| Braeburn Inc. | 9 | $190 |
| Orexo US, Inc. | 11 | $162 |
| Neurocrine Biosciences, Inc. | 7 | $121 |
| Bausch Health US, LLC | 5 | $102 |
| Collegium Pharmaceutical, Inc. | 4 | $89 |
| Adlon Therapeutics L.p. | 5 | $86 |
| Noven Therapeutics, LLC | 4 | $81 |
| Novo Nordisk | 4 | $60 |
| Vertical Pharmaceuticals, LLC | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| Jazz Pharmaceuticals Inc. | 3 | $53 |
| Alfasigma USA, Inc. | 3 | $46 |
| Hikma Pharmaceuticals USA | 2 | $45 |
| Shire North American Group Inc | 3 | $38 |
| Validus Pharmaceuticals LLC | 5 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Tempus AI, Inc | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Neuronetics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$287
How this compares
$11,409 in reported general payments places this provider in the 85th percentile of 160 child & adolescent psychiatry providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 78 | $10,686 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $6,062 |
| Clozapine | 18 | $2,393 |
| Buprenorphine Hcl | 41 | $1,419 |
| Bupropion XlBupropion Hcl | 35 | $501 |
| Buspirone Hcl | 15 | $232 |
| Gabapentin | 19 | $228 |
| Lamotrigine | 14 | $198 |
| Clonazepam | 50 | $144 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $118 |
| Mirtazapine | 12 | $102 |
| Quetiapine Fumarate | 11 | $97 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 18 | $94 |
| Propranolol Hcl | 18 | $74 |
| Fluoxetine Hcl | 12 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl | $45 | $12,105119 claims |
| Indivior Inc.Suboxone | $353 | $6,06215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 160 child & adolescent psychiatry providers in Ohio.
Other child & adolescent psychiatry in Canton
- Melissa DelbelloCincinnati$4.5M
- Luis Patino DuranCincinnati$652K
- Nora McNamaraCleveland$567K
- Robert FindlingCleveland$421K
- Craig EricksonCincinnati$275K
- Ernest PedapatiCincinnati$257K
- Lawrence ArnoldColumbus$215K
- Rick BowersMoraine$182K
- Kelli DominickCincinnati$175K
- Amy Hoisington-StabileColumbus$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.